NCT03984812 - Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

March 23, 2020

Study Completion Date

March 23, 2020

Conditions

HIV Infections

Interventions

DRUG

GSK3732394

It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL

DRUG

Placebo

Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.

Trial Locations (1)

21225

GSK Investigational Site, Baltimore